Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT07263035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 600 participants
- Sponsor
- Lakeland Regional Health Systems, Inc.
- Registry
-
NCT07263035
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07263035. Randomized; no masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2027-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure
- Acronym
- US-DASH
- Condition
- Heart Failure
- Condition
- Heart Failure - NYHA II - IV
- Condition
- Heart Failure Acute
- Condition
- Acute Heart Failure (AHF)
- Intervention (Drug)
- Furosemide intravenous solution
- Intervention (Drug)
- Furosemide intravenous solution
- Intervention (Drug)
- Furosemide intravenous solution
- Lead sponsor
- Lakeland Regional Health Systems, Inc.
Record details
- Record id
cardio:ct-nct07263035- Content hash
4524c08a7692d376b669ccfc9f84c18c5358c0cb4cf0d22cbda49ec70bb58284